Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Bimekizumab

    - PMLiVE

    UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

    The study demonstrated a sustained reduction in seizures for patients

    - PMLiVE

    Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

    Approximately 125 million people globally are living with some form of psoriasis

    - PMLiVE

    UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

    CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

    - PMLiVE

    UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

    Approximately 125 million people worldwide are affected by some form of psoriasis

    - PMLiVE

    Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis

    The inflammatory condition affects approximately 30% of psoriasis patients

    - PMLiVE

    UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

    The inflammatory skin disease affects approximately one in every 100 people in the US

    - PMLiVE

    UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab

    The drug showed benefits across key secondary endpoints, including tau accumulation

    - PMLiVE

    UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa

    The inflammatory skin disease affects about 1% of the population in most studied countries

    - PMLiVE

    Acelyrin shares positive phase 3 results for izokibep in hidradenitis suppurativa

    Despite the promising readout, the company said it will not be moving forward with the candidate in the inflammatory skin condition

    - PMLiVE

    UCB’s Bimzelx granted MHRA approval to treat hidradenitis suppurativa in adults

    The authorisation applies to patients who have had an inadequate response to conventional systemic HS therapy

    - PMLiVE

    UCB shares positive phase 3 results for Zilbrysq in generalised myasthenia gravis

    Zilbrysq is the first C5 inhibitor to show a clinically meaningful reduction of fatigue in the rare autoimmune disease

    - PMLiVE

    UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults

    The regulator’s decision marks Bimzelx’s fourth approved indication within the EU

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links